Please login to the form below

Not currently logged in
Email:
Password:

Merck Serono and Takeda reconsider matuzumab development

Merck Serono has announced it is considering whether to further develop its humanised monoclonal antibody drug matuzumab for metastatic colorectal cancer patients.

Merck Serono has announced it is considering whether to further develop its humanised monoclonal antibody drug matuzumab for metastatic colorectal cancer patients.

According to the company, a phase II trial investigating matuzumab in combination with irinotecan in patients with metastatic colorectal cancer (mCRC) who had already failed on multiple prior treatments, including irinotecan, has not met its predefined endpoint of activity.

Swtizerland-based Merck Serono is co-developing matuzumab with Japanese company Taked. According to a statement by Merck Serono, both companies share the view that the study results do not meet expectations.

The companies will continue to study the drug in other tumours including non-small cell lung cancer (NSCLC).

29th August 2007

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

Ask the writers: Transitioning from academia to medical writing
Porterhouse Medical's talented writers talk about their transition from academia and give advice to those people considering a career in medical writing...
Strategic launch planning: familiar framework, new mindset
By James Aird...
Guide
How to embrace behavioural science principles in healthcare MR...